medigraphic.com
Academia Mexicana de Neurología, A.C.

2016, Number 3

<< Back Next >>

Rev Mex Neuroci 2016; 17 (3)

Classical models of induction of Parkinsonism and its comparison with the pathophysiology of Parkinson disease

Velarde-Avalos A, Arias- Rincón AN, Arrezola-Tejeda FC, Castañedad-Achutigui FD

Language: Spanish
References: 39
Page: 90-99
PDF size: 1705.68 Kb.


ABSTRACT

Parkinson disease (PD) is a neurodegenerative disorder characterized mainly by the death of dopaminergic cells in the substantia nigra (SN) pars compacta and decrease in the levels of dopamine in striatal terminals, responsible for most of the characteristic motor abnormalities. These biochemical and motor disturbances are reproduced by different drugs (amphetamines, reserpine), models based on the use of pesticides (paraquat and rotenone) and models where toxic substances (MPTP and 6-hydroxydopamine) were used. All these models are characterized by structural or functional changes induced by nigrostriatal dopaminergic transmission. However, none of these models is able to reproduce in full all pathophysiological processes and clinical features in this condition are presented. So there will be a review of the main models based on the use of pesticides, pharmacological models and use of toxins and their relevance to the study of disease, with special focus on the mechanisms of action of these models


REFERENCES

  1. Mulcahy P, Walsh S, Paucard A, Rea K, Dowd E. Characterisation of a novel model of Parkinson’s disease by intra-striatal infusion of the pesticide rotenone. Neuroscience 2011; 181: 234-242.

  2. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson’s disease. Trends Pharmacol Sci 2010; 31: 141-142.

  3. Masatoshi Inden, Yoshihisa Kitamura, Mari Abe, Aya Tamaki, Kazuyuki Takata and Takashi Taniguchi. Parkinsonian Rotenone Mouse Model: Reevaluation of Long-Term Administration of Rotenone in C57BL/6 Mice. Biol Pharm Bull 2011; 34: 92-96.

  4. Won-Seok Choi, Richard D. Palmiter, Zhengui Xia1. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model. J Cell Biol 2011; 192: 873–882.

  5. Neha Sharma, Bimla Nehrucorresponding. Beneficial Effect of Vitamin E in Rotenone Induced Model of PD: Behavioural, Neurochemical and Biochemical Study. Exp Neurobiol 2013; 22: 214–223.

  6. Nian Xiong, Jing Xiong, Min Jia, Ling Liu, Xiaowei Zhang, Zhenzhen Chen, et al. The role of autophagy in Parkinson’s disease: rotenone-based modeling. Behavioral and Brain Functions 2013; 9: 13.

  7. Genaro Gabriel Ortiz, Fermín Paul Pacheco Moisés, Miguel Ángel Macías-Islas, Francisco Javier Jiménez-Gil, Alejandra G. Miranda-Díaz, Luís J. Flores-Alvarado, et. al. Toxicidad de plaguicidas y su asociación con la enfermedad de Parkinson. Arch Neurocien (Mex) 2011; 16: 33-39.

  8. Phillip M. Rappolda, Mei Cuia, Adrianne S. Chessera, Jacqueline Tibbetta, Jonathan C. Grimaa, Lihua Duanc, et al. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. PNAS 2011; 108: 20766–20771.

  9. Le W, Sayana P, Jankovic J. Animal models of Parkinson’s disease: a gateway to therapeutics?. Neurotherapeutics 2014; 11: 92-110.

  10. R. Nisticò, B. Mehdawy, S. Piccirilli and N. Mercuri. Paraquat- and Rotenone-Induced Models of Parkinson’s Disease. International Journal of Immunopathology and Pharmacology 2011; 24: 313- 22.

  11. C Berry, C La Vecchia, and P Nicotera. Paraquat and Parkinson’s disease. Cell Death and Differentiation 2010; 17: 1115-1125.

  12. Jun Peng, Li Peng, Fang Feng Stevenson, Susan R. Doctrow, and Julie K. Andersen. Iron and Paraquat as Synergistic Environmental Risk Factors in Sporadic Parkinson’s Disease Accelerate Age-Related Neurodegeneration. The Journal of Neuroscience 2007; 27: 6914-6922.

  13. Hongxia Zhou, Cao Huang, Jianbin Tong, Xu-Gang Xia. Early Exposure to Paraquat Sensitizes Dopaminergic Neurons to Subse-quent Silencing of PINK1 Gene Expression in Mice. International Journal of Biological Sciences 2011; 7: 1180-1187.

  14. 14. Arati A. Inamdar, Anathbandhu Chaudhuri, and Janis O’Donnell. The Protective Effect of Minocycline in a Paraquat-Induced Parkinson’s Disease Model in Drosophila is Modified in Altered Genetic Backgrounds. Parkinson’s Disease 2012; 2012: 938528.

  15. Matthews M, Bondi C, Torres G, Moghaddam B. Reduced presynaptic dopamine activity in adolescent dorsal striatum. Neuropsychopharmacology 2013; 38: 1344-51.

  16. Price MT, Fibiger HC. Apomorphine and amphetamine stereotypy after 6- hydroxydopamine lesions of the substantia nigra. Eur J Pharmacol 1974; 29: 249-252.

  17. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alphasynuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239-52.

  18. Przedborski S, Tieu K. 2006. Toxic animal models. InNeurodegenerative diseases (ed. Beal MF, et al.), pp. 196–221. Cambridge University Press, Cambridge.

  19. Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, Miller GW. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J Neurochem 2008; 106: 2205–2217.

  20. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959; 11: 490-493.

  21. 30. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5- hydroxytryptophan as reserpine antagonists. Nature. 1957; 180: 1200.

  22. Tieu K. A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med 2011; 1: a009316.

  23. Heeringa M.J. & Abercrombie E.D. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J. Neurochem 1995; 65: 192–200.

  24. Benazzouz A, Breit S, Koudsie A, Pollak P, Krack P, Benabid AL. Intraoperative microrecordings of the subthalamic nucleus in Parkinson’s disease. Mov Disord 2002; 17: S145-S149.

  25. Utley JD, Carlsson A. Relative effects of L-DOPA and its methyl ester given orally or intraperitoneally to reserpine-treated mice. Acta Pharmacol Toxicol (Copenh) 1965; 23: 189-193.

  26. Singer TP, Castagnoli N, Jr., Ramsay RR, Trevor AJ. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2, 3,6- tetrahydropyridine. J Neurochem 1987; 49: 1-8.

  27. Cohen G. Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm Suppl 1990; 32: 229-238.

  28. Ramsay RR, Kowal AT, Johnson MK, Salach JI, Singer TP. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1, 2, 3,6- tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys 1987; 259: 645-649.

  29. Bové J, Perier C. Neurotoxin-based models of Parkinson’s disease. Neuroscience 2012; 211:51-76.

  30. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 2000; 30: 171-182.

  31. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Neurodegeneration 1995; 4: 257-69.

  32. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, et al. JNKmediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc Natl Acad Sci 2004; 101: 665-670.

  33. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997; 77: 1037-48.

  34. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein upregulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000; 74: 721-729.

  35. Bezard E, Dovero S, Bioulac B, Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 1997; 148: 288-292.

  36. 36. Bezard E, Dovero S, Bioulac B, Gross CE. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett 1997; 234: 47-50.

  37. Thoenen H, Tranzer JP. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-Hydroxydopamine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1968; 261: 271-288.

  38. Ungerstedt, U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol 1968; 5: 107-110.

  39. Alarcón Aguilar Adriana, Abel Santamaría del Ángel, Mina Königsberg Fainstein. Modelos neurotóxicos de la enfermedad de parkinson y disfunción mitocondrial. REB 2010; 29: 91-99.




2020     |     www.medigraphic.com